Article Text

Download PDFPDF
Long-term Benefit of Tumor Volume-Directed Involved Field Radiation Therapy in the Management of Recurrent Ovarian Cancer
  1. Kevin Albuquerque, MD,
  2. Mona Patel, MD,
  3. Margaret Liotta, DO,
  4. Matthew Harkenrider, MD,
  5. Rong Guo, MS,
  6. Jr William Small, MD, FACR, FASTRO and
  7. Potkul Ronald, MD, FACS, FACOG
  1. * Department of Radiation Oncology, Loyola University Medical Center, Maywood, IL;
  2. University of Texas Southwestern Medical Center, Moncrief Radiation Oncology Center, Dallas, TX; Departments of
  3. Anesthesiology, and
  4. § Gynecologic Oncology, Loyola University Medical Center, Maywood, IL; and ||Massachusetts Eye and Ear Infirmary, Biostatistics Core, Harvard Medical School, Boston, MA.
  1. Address correspondence and reprint requests to Kevin Albuquerque, MD, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-9183. E-mail: kevin.albuquerque{at}


Objectives This study aimed to report on long-term effectiveness of involved field radiation therapy (IFRT) in the salvage of localized recurrent ovarian cancer (ROC).

Methods A retrospective analysis of 27 patients with a diagnosis of epithelial ovarian cancer who received tumor volume-directed IFRT for localized extraperitoneal recurrences (either as consolidation after cytoreductive surgery (CRS) or as attempted salvage if unresectable) forms the basis of this report. All patients were heavily pretreated with multiple chemotherapy regimens. Involved field radiation therapy was primarily with external beam (median dose, 50.4 Gy). Local recurrence-free survival (LRFS) was defined as freedom from in-field recurrences and was considered as a measure of effectiveness of radiotherapy. Statistical analyses evaluated association between disease-free survival, overall survival, LRFS, and various prognostic factors. Comparison was also made with a similar but unmatched cohort with localized recurrences salvaged by additional chemotherapy instead of local therapies (NIFRT group).

Results Of 27 patients, 17 had optimal CRS before RT. The actuarial survival at 5 and 10 years (in parenthesis) from date of radiation were LRFS (70% and 60%), overall survival (30% and 19%), and disease-free survival (33% and 20%). None of the NIFRT patients survived beyond 5 years from initiation of salvage chemotherapy.

Conclusions Long-term follow-up in this selected series confirmed the benefit of IFRT (±CRS) in localized ROC. Chemotherapy salvage in a similar NIFRT group was not equivalent, suggesting a role for locoregional therapies in selected patients with ROC.

  • Recurrent ovarian cancer
  • Salvage treatment
  • Involved field radiation therapy
  • Cytoreductive surgery

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.